Industry Reports
The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
The ultimate guide to the complex web of interactions within the U.S. prescription distribution and reimbursement system more >
The 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
The most comprehensive tool for analyzing the economic and business realities of the U.S. pharmaceutical distribution industry. more >
From The Drug Channels Blog
Tuesday, September 1, 2026
The Private Label Biosimilar Paradox in Medicare Part D
By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not more >
Friday, August 28, 2026
Medicare, Medicaid, and Reverification: What Patient Support Programs Need to Know Before January 2027
Today's guest post comes from Bryce Aronson, Director of Business Development at AssistRx. Bryce covers three considerations taking effect in January 2027—the end of Medicare Part more >